Table 1.

Summary of clinical characteristics and PD-L1 status for the study cohort

Patient	Tumor	Age (years)	Descriptiona	Location	Size (cm)	Alk	Tumord PD-L1	IC PD-L1
1	T1	0.06	Primary	Heart	2.5	Neg	Mixed	Pos
2	T2	0.42	Primary	Mediastinum	4.0	Pos	Adaptive	Pos
3	T3	1.08	Primary	Extremity	5.5	Pos	Adaptive	Pos
4	T4	2	Primary	Mesenteric mass	9.5	Pos	Neg	Neg
5	T5	2.3	Primary	Liver	12.5	Pos	Mixed	Pos
	T6	2.7	Metastasis	Omentum	4.5	Pos	Mixed	Pos
	T7	2.7	Metastasis	Bowel serosa	1.7	Pos	Adaptive	Pos
6	T8	4	Primary	Trachea	1.7	Pos	Neg	Pos
7	T9	9	Primary	Abdomen	20	Pos	Mixed	Pos
	T10	9	Recurrence	Abdomen	6.5	Pos	Mixed	Pos
8	T11	9	Primary	Lung	1.3	Pos	Neg	Pos
9	T12	10	Primary	Extremity	3	Negb	Adaptive	Pos
10	T13	12	Primary	Brain	1.9	Negc	Adaptive	Neg
11	T14	26	Primary	Pulmonary artery	5	Neg	Mixed	Pos
12	T15	27	Primary	Lung	1.2	Pos	Neg	Pos
13	T16	28	Primary	Placenta	3.2	Pos	Neg	Pos
14	T17	30	Primary	Pelvic mass	10	Negb	Neg	Pos
15	T18	35	Metastasis (lung)	Rectus sheath	9	Pos	Neg	Neg
16	T19	36	Metastasis (lung)	Brain	3.1	Pos	Neg	Neg
17	T20	36	Primary	Lung	4.5	Pos	Neg	Neg
18	T21	37	Primary	Bladder	4	Pos	Mixed	Pos
19	T22	39	Primary	Bladder	3.6	Pos	Mixed	Pos
20	T23	42	Primary	Lung	1	Pos	Neg	Pos
21	T24	43	Primary	Bladder	2.2	Pos	Mixed	Pos
22	T25	44	Primary	Lung	1.5	Pos	Adaptive	Pos
23	T26	55	Primary	Liver	17.5	Negb	Mixed	Pos
24	T27	57	Primary	Lung	0.7	Negb	Adaptive	Pos
25	T28	61	Recurrencee	Pelvic mass	6.8	Neg	Mixed	Pos
26	T29	61	Primaryf	Lung	NA	Pos	Adaptive	Pos
	T30	61	Primaryf	Lung	9.5	Pos	Mixed	Pos
	T31	65	Metastasisf	Chest wall	7	Pos	Mixed	Pos
	T32	66	Metastasisf	Kidney	9	Pos	Const.	Neg
	T33	67	Metastasisf	Chest wall	1.5	Pos	Adaptive	Pos
27	T34	74	Primary	Epiglottis	0.5	Pos	Neg	Neg
28	T35	77	Primary	Bladder	2	Pos	Adaptive	Pos

^aWhen only the metastasis is present, the primary location is noted in parentheses

^bROS1 rearrangement negative

^cROS1 rearrangement positive

^dFor specimens positive for tumor cell PD-L1 expression, the pattern is noted as adaptive, constitutive (Const.), or mixed

^ePrior radiation

^fPrior chemotherapy for another malignancy

Abbreviations: Immune cell (IC), positive (Pos), negative (Neg);